ArticleMedicine2026
Risk factors for antipsychotic- and antidepressant-associated liver function abnormalities: A retrospective unmatched case-control study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antipsychotics (APs) and antidepressants (ADs) are the primary therapies for psychiatric disorders. However, drug-induced liver injury and liver biochemical abnormalities during treatment with APs and/or ADs remain significant safety concerns in clinical practice. Identifying factors associated with liver function abnormalities at an early stage may help support appropriate monitoring and preventive measures. A retrospective unmatched case-control study was conducted, including 708 discharged patients (354 cases and 354 controls) from Xuzhou Oriental Hospital Affiliated to Xuzhou Medical University between January and December 2025. Univariate and multivariable logistic regression analyses were performed to identify factors associated with liver function abnormalities. Olanzapine was the most frequently recorded AP/AD exposure among patients with liver function abnormalities (57.34%). Multivariable logistic regression showed that male sex (odds ratio [OR] = 1.51, 95% confidence interval [CI], 1.07-2.11), age ≥60 years (OR = 5.02, 95% CI, 2.48-10.16), obesity (OR = 3.60, 95% CI, 1.24-10.43), dysglycemia (OR = 2.59, 95% CI, 1.37-4.91), dyslipidemia (OR = 2.18, 95% CI, 1.55-3.05), length of stay (OR = 1.014, 95% CI, 1.003-1.025), and medication history ≤1 year (OR = 2.98, 95% CI, 1.87-4.74) were independently associated with liver function abnormalities. Liver function abnormalities occurring in psychiatric patients after AP and/or AD treatment mainly consisted of liver biochemical abnormalities. Olanzapine was the most frequently recorded AP/AD exposure among affected patients, but this descriptive finding should not be interpreted as indicating a comparative hepatotoxicity risk. These findings may help clinical pharmacists identify patients who require closer liver function monitoring, but multicenter validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.